ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2010

Jun 7, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2010-06-03

Reporting Person: MARTINO MICHAEL A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-06-03	Common Stock	M	11641	$2.69	Acquired	22641	Direct
2010-06-03	Common Stock	S	11641	$14.4564	Disposed	11000	Direct
2010-06-03	Common Stock	M	2359	$6.66	Acquired	13359	Direct
2010-06-03	Common Stock	S	2359	$14.4564	Disposed	11000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-06-03	stock option (right to buy)	$2.69	M	11641	Disposed	2015-10-28	Common Stock (11641)	Direct
2010-06-03	Stock option (right to buy)	$6.66	M	2359	Disposed	2018-03-18	Common Stock (2359)	Direct

Footnotes

F1: This is the weighted average price. The prices ranged from $14.35 to $14.52. The reporting person undertakes to provide on request a detailed breakout of the pricing.